secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK:        0001439222
Form:       8-K
Filed at:   2026-04-29T23:59:59+00:00
Accession:  0001439222-26-000071
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agios Q1 mitapivat revenue $20.7M; 242 AQVESME scrips; sCD sNDA plan in Q2
--------------------------------------------------------------------------

- Worldwide mitapivat net revenue $20.7M in Q1 2026, up from $8.7M in Q1 2025.
- 242 AQVESME prescriptions for thalassemia by U.S. REMS-certified physicians as of March 31, 2026.
- Plans to submit mitapivat sNDA for sickle cell disease under accelerated approval pathway in Q2 2026.
- Net loss $99.1M in Q1 2026 vs $89.3M in Q1 2025.
- Cash and equivalents $1.0B as of March 31, 2026, down from $1.2B at Dec 31, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439222/000143922226000071/0001439222-26-000071-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439222/000143922226000071/agio-20260429.htm
  HTML page:      https://secwatch.observer/filing/0001439222-26-000071

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer